Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.